Excessive Daytime Sleepiness Pipeline Drugs Analysis Report 2025: Comprehensive Review of Ongoing Trials and Emerging Therapeutics | DelveInsight

DelveInsight's "Excessive Daytime Sleepiness Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Excessive Daytime Sleepiness pipeline landscape. It covers the Excessive Daytime Sleepiness Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Excessive Daytime Sleepiness Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Excessive Daytime Sleepiness Pipeline? Click here to explore the therapies and trials making headlines @ Excessive Daytime Sleepiness Pipeline Outlook Report [https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Excessive Daytime Sleepiness Pipeline Report

* On 02 October 2025, Avadel announced a study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218 Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose of twice nightly sodium oxybate IR or mixed salts oxybate (regardless of whether they participated in the REST-ON study), or subjects who are naive to oxybate therapy (i.e., FT218, twice nightly sodium oxybate IR or mixed salts oxybate).
* DelveInsight's Excessive Daytime Sleepiness Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Excessive Daytime Sleepiness treatment.
* The leading Excessive Daytime Sleepiness Companies such as Suven Life Sciences Limited, NLS Pharmaceutics, Axsome Therapeutics, Zevra Therapeutics, Jazz Pharmaceuticals and others.
* Promising Excessive Daytime Sleepiness Therapies such as Pitolisant, PF-03654746, BEN-2001, AXS-12 (reboxetine), FT218, Solriamfetol, THN102 and others.

Want to know which companies are leading innovation in Excessive Daytime Sleepiness? Dive into the full pipeline insights @ Excessive Daytime Sleepiness Clinical Trials Assessment [https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Excessive Daytime Sleepiness Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Excessive Daytime Sleepiness Pipeline Report also highlights the unmet needs with respect to the Excessive Daytime Sleepiness.

Excessive Daytime Sleepiness Overview

Excessive daytime sleepiness can be symptomatic of several underlying conditions rather than being a standalone ailment. Any disruption in an individual's ability to obtain restorative sleep at night can manifest as excessive daytime sleepiness. Common culprits contributing to this condition include sleep apnea, restless leg syndrome (RLS), depression, hypersomnia, and narcolepsy. Sleep apnea poses a potentially serious threat, marked by abnormal breathing patterns during sleep.

Excessive Daytime Sleepiness Emerging Drugs Profile

* AXS-12: Axsome Therapeutics

AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. It is thought to modulate noradrenergic activity to promote wakefulness, maintain muscle tone and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries where it's approved for the treatment of depression. In narcolepsy, AXS-12 is supported by positive pre-clinical and Phase II clinical results. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Excessive Daytime Sleepiness.

* ALKS 2680: Alkermes

ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. Orexin neuropeptides are important regulators of the sleep/wake cycle through OX2R activation, and loss of orexinergic neurons in the brain is associated with excessive daytime sleepiness and cataplexy in narcolepsy.1 ALKS 2680 was designed to address the underlying pathology of narcolepsy with the goal of improving duration of wakefulness and providing cataplexy control. Once-daily oral administration of ALKS 2680 is currently being evaluated in a phase II study for the treatment of idiopathic hypersomnia.

If you're tracking ongoing Excessive Daytime Sleepiness Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Excessive Daytime Sleepiness Treatment Drugs [https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Excessive Daytime Sleepiness Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Excessive Daytime Sleepiness with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Excessive Daytime Sleepiness Treatment.
* Excessive Daytime Sleepiness Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Excessive Daytime Sleepiness Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Excessive Daytime Sleepiness market.

Excessive Daytime Sleepiness Companies

Suven Life Sciences Limited, NLS Pharmaceutics, Axsome Therapeutics, Zevra Therapeutics, Jazz Pharmaceuticals and others.

Excessive Daytime Sleepiness Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Excessive Daytime Sleepiness Products have been categorized under various Molecule types such as,

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule

From emerging drug candidates to competitive intelligence, the Excessive Daytime Sleepiness Pipeline Report covers it all - check it out now @ Excessive Daytime Sleepiness Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Excessive Daytime Sleepiness Pipeline Report

* Coverage- Global
* Excessive Daytime Sleepiness Companies- Suven Life Sciences Limited, NLS Pharmaceutics, Axsome Therapeutics, Zevra Therapeutics, Jazz Pharmaceuticals and others.
* Excessive Daytime Sleepiness Therapies - Pitolisant, PF-03654746, BEN-2001, AXS-12 (reboxetine), FT218, Solriamfetol, THN102 and others.
* Excessive Daytime Sleepiness Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Excessive Daytime Sleepiness Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Excessive Daytime Sleepiness Treatment landscape in this detailed analysis @ Excessive Daytime Sleepiness Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Excessive Daytime Sleepiness: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Excessive Daytime Sleepiness - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AXS-12: Axsome Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ALKS 2680: Alkermes
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Excessive Daytime Sleepiness Key Companies
* Excessive Daytime Sleepiness Key Products
* Excessive Daytime Sleepiness- Unmet Needs
* Excessive Daytime Sleepiness- Market Drivers and Barriers
* Excessive Daytime Sleepiness- Future Perspectives and Conclusion
* Excessive Daytime Sleepiness Analyst Views
* Excessive Daytime Sleepiness Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=excessive-daytime-sleepiness-pipeline-drugs-analysis-report-2025-comprehensive-review-of-ongoing-trials-and-emerging-therapeutics-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.